{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:44:26Z","timestamp":1792032266214,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"DOI":"10.1038\/s41391-026-01165-w","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:53:27Z","timestamp":1792029207000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic and oncological effects of metformin added to ADT in prostate cancer: systematic review and meta-analysis including STAMPEDE"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6399-9550","authenticated-orcid":false,"given":"Farah","family":"Fakhri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2131-0371","authenticated-orcid":false,"given":"Zeid","family":"Alkhairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5190-417X","authenticated-orcid":false,"given":"Talal","family":"Sarhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4053-8484","authenticated-orcid":false,"given":"Gozeel","family":"Imran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1787-4533","authenticated-orcid":false,"given":"Lyaba","family":"Imran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8783-626X","authenticated-orcid":false,"given":"Raeesah","family":"Moola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3419-4118","authenticated-orcid":false,"given":"Radwan","family":"Darwish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6088-7490","authenticated-orcid":false,"given":"Abdulrahman","family":"Al-Majmuei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"1165_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1165_CR2","first-page":"293","volume":"1","author":"C Huggins","year":"1941","unstructured":"Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293\u20137.","journal-title":"Cancer Res"},{"key":"1165_CR3","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352\u201360.","journal-title":"N Engl J Med"},{"key":"1165_CR4","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338\u201351.","journal-title":"N Engl J Med"},{"key":"1165_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jnci\/djp404","volume":"102","author":"NL Keating","year":"2010","unstructured":"Keating NL, O\u2019Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102:39\u201346.","journal-title":"J Natl Cancer Inst"},{"key":"1165_CR6","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.eururo.2014.11.039","volume":"68","author":"C Bosco","year":"2015","unstructured":"Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2015;68:386\u201396.","journal-title":"Eur Urol"},{"key":"1165_CR7","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/j.juro.2012.11.017","volume":"189","author":"PJ Saylor","year":"2013","unstructured":"Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2013;189:S34\u201342.","journal-title":"J Urol"},{"key":"1165_CR8","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1001\/jama.2011.1745","volume":"306","author":"PL Nguyen","year":"2011","unstructured":"Nguyen PL, Je Y, Schutz FAB, Hoffman KE, Hu JC, Parekh A, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306:2359\u201366.","journal-title":"JAMA"},{"key":"1165_CR9","first-page":"671","volume":"73","author":"DA Galvao","year":"2018","unstructured":"Galvao DA, Taaffe DR, Spry N, Newton RU, Chambers SK, Risbridger G, et al. Exercise preserves physical function in prostate cancer patients with bone metastases and improves hormonal and immune status in those without bone involvement: a multisite randomised trial. Eur Urol. 2018;73:671\u20139.","journal-title":"Eur Urol"},{"key":"1165_CR10","doi-asserted-by":"publisher","unstructured":"Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II\u20142024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2024;86:164\u201382. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.010.","DOI":"10.1016\/j.eururo.2024.04.010"},{"key":"1165_CR11","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1158\/1940-6207.CAPR-10-0175","volume":"3","author":"M Pollak","year":"2010","unstructured":"Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Philos). 2010;3:1060\u20135.","journal-title":"Cancer Prev Res (Philos)"},{"key":"1165_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrendo.2013.256","volume":"10","author":"I Pernicova","year":"2014","unstructured":"Pernicova I, Korbonits M. Metformin: mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014;10:143\u201356.","journal-title":"Nat Rev Endocrinol"},{"key":"1165_CR13","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1038\/sj.onc.1211024","volume":"27","author":"I Ben Sahra","year":"2008","unstructured":"Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008;27:3576\u201386.","journal-title":"Oncogene"},{"key":"1165_CR14","doi-asserted-by":"crossref","first-page":"266","DOI":"10.14740\/wjon1602","volume":"14","author":"N Bansal","year":"2023","unstructured":"Bansal N, Bhatt YM, Patel P, Pathak N. Metformin and prostate cancer: biologic mechanisms and clinical outcomes. World J Oncol. 2023;14:266\u201376.","journal-title":"World J Oncol"},{"key":"1165_CR15","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S1470-2045(25)00231-1","volume":"26","author":"S Gillessen","year":"2025","unstructured":"Gillessen S, Murphy L, James ND, Sachdeva A, El-Taji O, Abdel-Aty H, et al. Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol. Lancet Oncol. 2025;26:1018\u201330. https:\/\/doi.org\/10.1016\/S1470-2045(25)00231-1.","journal-title":"Lancet Oncol"},{"key":"1165_CR16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1165_CR17","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"1165_CR18","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1002\/sim.1009","volume":"20","author":"J Hartung","year":"2001","unstructured":"Hartung J, Knapp G. A refined method for the meta-analysis of controlled clinical trials with binary outcome. Stat Med. 2001;20:3875\u201389.","journal-title":"Stat Med"},{"key":"1165_CR19","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373:737\u201346.","journal-title":"N Engl J Med"},{"key":"1165_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401\u20136.","journal-title":"J Clin Epidemiol"},{"key":"1165_CR21","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1111\/j.1464-410X.2011.10555.x","volume":"109","author":"JP Nobes","year":"2012","unstructured":"Nobes JP, Langley SE, Klopper T, Russell-Jones D, Laing RW. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int. 2012;109:1495\u2013502.","journal-title":"BJU Int"},{"key":"1165_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000448691","volume":"98","author":"W Zhu","year":"2017","unstructured":"Zhu W, Xu H, Ma J, Guo J, Xue W, Gu B, et al. An open-label pilot study of metformin as a concomitant therapy on patients with prostate cancer undergoing androgen deprivation treatment. Urol Int. 2017;98:79\u201384. https:\/\/doi.org\/10.1159\/000448691.","journal-title":"Urol Int"},{"key":"1165_CR23","doi-asserted-by":"publisher","unstructured":"Fleshner N, Bernardino RM, Izawa J, Drachenberg D, Saranchuk J, Fairey A, et al. Metformin active surveillance trial in low-risk prostate cancer. J Clin Oncol. 2025; [Epub ahead of print]. https:\/\/doi.org\/10.1200\/JCO-25-01070.","DOI":"10.1200\/JCO-25-01070"},{"key":"1165_CR24","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.21608\/ejhm.2022.223160","volume":"87","author":"HA Alagizy","year":"2022","unstructured":"Alagizy HA, Metwaly HM, Shehata MA, Alhassanin SA, Abdel Moneum RA, El Dosouky AE. Effect of adding metformin to the combined androgen deprivation therapy as frontline treatment in metastatic hormone-sensitive prostate cancer patients. Egypt J Hosp Med. 2022;87:1193\u2013203.","journal-title":"Egypt J Hosp Med"},{"key":"1165_CR25","doi-asserted-by":"publisher","unstructured":"Eigl BJ, Chi K, Annala M, Bernstein M, Fallone V, Fizazi K, et al. Metformin as prevention and intervention for metabolic syndrome in men on androgen deprivation therapy for prostate cancer (PRIME): a randomised, double-blind, placebo-controlled trial. J Urol. 2025; [Epub ahead of print]. https:\/\/doi.org\/10.1097\/JU.0000000000004695.","DOI":"10.1097\/JU.0000000000004695"},{"key":"1165_CR26","first-page":"622","volume":"117","author":"N Usmani","year":"2023","unstructured":"Usmani N, Butson L, Parliament M, Ghosh S, Abdi A, Pertschy D, et al. Metformin during androgen deprivation therapy for prostate cancer (PREMIUM): a phase II randomised double-blind placebo-controlled trial. Int J Radiat Oncol Biol Phys. 2023;117:622\u201332.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1165_CR27","doi-asserted-by":"publisher","first-page":"435.e1","DOI":"10.1016\/j.urolonc.2021.05.020","volume":"39","author":"R Alghandour","year":"2021","unstructured":"Alghandour R, Ebrahim MA, Elshal AM, Ghoneem E, Abo-Zeid MA, Swellam M, et al. Repurposing metformin as anticancer drug: randomized controlled trial in advanced prostate cancer (MANSMED). Urol Oncol. 2021;39:435.e1\u2013435.e9.","journal-title":"Urol Oncol"},{"key":"1165_CR28","doi-asserted-by":"publisher","first-page":"622","DOI":"10.18632\/oncotarget.28458","volume":"14","author":"D Mahalingam","year":"2023","unstructured":"Mahalingam D, Hanni S, Serritella AV, Fountzilas C, Michalek J, Hernandez B, et al. Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer. Oncotarget. 2023;14:622\u201336.","journal-title":"Oncotarget"},{"key":"1165_CR29","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1001\/jama.2022.6147","volume":"327","author":"PJ Goodwin","year":"2022","unstructured":"Goodwin PJ, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, et al. Effect of metformin vs placebo on invasive disease-free survival in patients with breast cancer: the MA.32 randomized clinical trial. JAMA. 2022;327:1963\u201373.","journal-title":"JAMA"},{"key":"1165_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-38285-w","volume":"9","author":"K He","year":"2019","unstructured":"He K, Hu H, Ye S, Wang H, Cui R, Yi L. The effect of metformin therapy on incidence and prognosis in prostate cancer: a systematic review and meta-analysis. Sci Rep. 2019;9:2218.","journal-title":"Sci Rep"},{"key":"1165_CR31","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/S1470-2045(23)00230-9","volume":"24","author":"CL Vale","year":"2023","unstructured":"Vale CL, Rydzewska LHM, Godolphin PJ, Fisher DJ, Kenig-Kozlowska JM, Nankivell MG, et al. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials. Lancet Oncol. 2023;24:783\u201397.","journal-title":"Lancet Oncol"},{"key":"1165_CR32","doi-asserted-by":"publisher","first-page":"e813","DOI":"10.1136\/bmj.e813","volume":"344","author":"A Bafeta","year":"2012","unstructured":"Bafeta A, Dechartres A, Trinquart L, Yavchitz A, Boutron I, Ravaud P. Impact of single centre status on estimates of intervention effects in trials with continuous outcomes: meta-epidemiological study. BMJ. 2012;344:e813.","journal-title":"BMJ"},{"key":"1165_CR33","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.cmet.2016.03.010","volume":"23","author":"NS Chandel","year":"2016","unstructured":"Chandel NS, Avizonis D, Reczek CR, Weinberg SE, Menz S, Neuhaus R, et al. Are metformin doses used in murine cancer models clinically relevant? Cell Metab. 2016;23:569\u201370.","journal-title":"Cell Metab"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01165-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01165-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01165-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:53:29Z","timestamp":1792029209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01165-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":33,"alternative-id":["1165"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01165-w","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"22 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study is a systematic review and meta-analysis of previously published randomised controlled trials. No primary data collection from human participants was performed, and no ethics committee approval was required. All data analysed are from published studies that received appropriate ethics approval from their respective institutions and were conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}